Maxim Group reaffirmed their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research note released on Tuesday morning. They currently have a $3.00 target price on the biotechnology company’s stock.
“Actinium announced that the Data Monitoring Committee (DMC) unanimously voted to recommend the Phase 3 SIERRA trial of Iomab-B to continue as planned. The interim safety look occurred at the 25% enrollment mark. The company will host a conference call Wednesday/tomorrow at 9am ET.”,” the firm’s analyst wrote.
A number of other analysts have also recently commented on the company. Zacks Investment Research raised Actinium Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, July 14th. B. Riley boosted their price target on Actinium Pharmaceuticals from $2.75 to $3.00 and gave the stock a buy rating in a research report on Thursday, July 12th. Five research analysts have rated the stock with a buy rating, Actinium Pharmaceuticals presently has a consensus rating of Buy and an average price target of $3.75.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Worth Venture Partners LLC purchased a new position in Actinium Pharmaceuticals in the 1st quarter worth approximately $140,000. Renaissance Technologies LLC raised its holdings in Actinium Pharmaceuticals by 1,269.5% in the 2nd quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 359,205 shares during the last quarter. Sio Capital Management LLC purchased a new position in Actinium Pharmaceuticals in the 1st quarter worth approximately $393,000. Sabby Management LLC purchased a new position in Actinium Pharmaceuticals in the 1st quarter worth approximately $729,000. Finally, Anson Funds Management LP purchased a new position in Actinium Pharmaceuticals in the 1st quarter worth approximately $1,502,000.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Recommended Story: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.